342 related articles for article (PubMed ID: 19476553)
1. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.
Yang L; Calingasan NY; Wille EJ; Cormier K; Smith K; Ferrante RJ; Beal MF
J Neurochem; 2009 Jun; 109(5):1427-39. PubMed ID: 19476553
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of creatine.
Beal MF
Amino Acids; 2011 May; 40(5):1305-13. PubMed ID: 21448659
[TBL] [Abstract][Full Text] [Related]
3. Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.
Sikorska M; Lanthier P; Miller H; Beyers M; Sodja C; Zurakowski B; Gangaraju S; Pandey S; Sandhu JK
Neurobiol Aging; 2014 Oct; 35(10):2329-46. PubMed ID: 24775711
[TBL] [Abstract][Full Text] [Related]
4. Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons.
Kooncumchoo P; Sharma S; Porter J; Govitrapong P; Ebadi M
J Mol Neurosci; 2006; 28(2):125-41. PubMed ID: 16679553
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
[TBL] [Abstract][Full Text] [Related]
6. An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo.
Liang LP; Huang J; Fulton R; Day BJ; Patel M
J Neurosci; 2007 Apr; 27(16):4326-33. PubMed ID: 17442816
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of chinonin in MPTP-induced C57BL/6 mouse model of Parkinson's disease.
Feng G; Zhang Z; Bao Q; Zhang Z; Zhou L; Jiang J; Li S
Biol Pharm Bull; 2014; 37(8):1301-7. PubMed ID: 24871044
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
Guo Z; Xu S; Du N; Liu J; Huang Y; Han M
Neurosci Lett; 2016 Mar; 616():152-9. PubMed ID: 26827716
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Sheline CT; Zhu J; Zhang W; Shi C; Cai AL
Neurodegener Dis; 2013; 11(1):49-58. PubMed ID: 22627004
[TBL] [Abstract][Full Text] [Related]
10. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.
Smith KM; Matson S; Matson WR; Cormier K; Del Signore SJ; Hagerty SW; Stack EC; Ryu H; Ferrante RJ
Biochim Biophys Acta; 2006 Jun; 1762(6):616-26. PubMed ID: 16647250
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
Moon M; Kim HG; Hwang L; Seo JH; Kim S; Hwang S; Kim S; Lee D; Chung H; Oh MS; Lee KT; Park S
Neurotox Res; 2009 May; 15(4):332-47. PubMed ID: 19384567
[TBL] [Abstract][Full Text] [Related]
12. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
[TBL] [Abstract][Full Text] [Related]
13. A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities.
Yang L; Calingasan NY; Chen J; Ley JJ; Becker DA; Beal MF
Exp Neurol; 2005 Jan; 191(1):86-93. PubMed ID: 15589515
[TBL] [Abstract][Full Text] [Related]
14. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
15. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
[TBL] [Abstract][Full Text] [Related]
16. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Klivenyi P; Gardian G; Calingasan NY; Yang L; Beal MF
J Mol Neurosci; 2003; 21(3):191-8. PubMed ID: 14645986
[TBL] [Abstract][Full Text] [Related]
17. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats.
Tariq M; Khan HA; Elfaki I; Al Deeb S; Al Moutaery K
Brain Res Bull; 2005 Sep; 67(1-2):161-8. PubMed ID: 16140176
[TBL] [Abstract][Full Text] [Related]
19. Creatine supplementation with exercise reduces α-synuclein oligomerization and necroptosis in Parkinson's disease mouse model.
Leem YH; Park JS; Park JE; Kim DY; Kim HS
J Nutr Biochem; 2024 Apr; 126():109586. PubMed ID: 38262563
[TBL] [Abstract][Full Text] [Related]
20. Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Heng Y; Zhang QS; Mu Z; Hu JF; Yuan YH; Chen NH
Toxicol Lett; 2016 Jan; 243():7-21. PubMed ID: 26723869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
